Autoantibodies to CD21 or other surface regulators could explain the lower CD21 levels commonly found on CLL cells; autoimmune phenomena are a feature of some CLL patients [37]. This evidence concerns the gene CR2 and B-cell chronic lymphocytic leukemia.